



enterprise europe

Boletín de Oportunidades de Cooperación:

Biotecnología y Salud

Boletín nº 143

mayo 2016

enterprise europe

Índice

Referencia	Título	Tipo Perfil
BOSK20160323001	Slovak producer of rabbit clonal monospecific antibodies and detection system for clinical pathology and research applications seeks partners	Business Offer
BOUK20160330001	UK sports nutrition company is seeking distributors for its range of premium sports nutritional supplements	Business Offer
BOPT20160309002	Joint-venture partner sought for an innovative software supporting responsible self-medication	Business Offer
TOES20160406001	Small electronic device for tracking Diabetes treatment	Technology Offer
TODE20160421001	Differential diagnosis of dementia with Lewy bodies and Parkinson's diseaseLithuanian company offers blood modeling and simulation services in capillaries and biologically active materials as well as transport across cells' membranes	Technology Offer
TOLT20160401001	Lithuanian company offers blood modeling and simulation services in capillaries and biologically active materials as well as transport across cells' membranes	Technology Offer
TOUK20160324001	UK university developing a novel device for assessing macular pigment optical density seeks pharmaceutical producers, lens/medical device manufacturers	Technology Offer

Business Offer

Slovak producer of rabbit clonal monospecific antibodies and detection system for clinical pathology and research applications seeks partners

Summary

A Slovak biotechnology company producing clonal monospecific rabbit antibodies for clinical pathology and research applications is seeking partners for distributing its products. The company has 140 ready to use antibodies already on the market and these can be distributed to the clients right away. Also, there is a capacity for new partners available for the development of a new antibodies and for the use of company's proteomic services in a form of services or manufacturing agreements.

Creation Date 23 March 2016
Expiration Date 22 April 2017
Reference BOSK20160323001

Details

Description

The Slovak company established in 2007 is looking for business partners to conclude a distribution services agreement, services agreement or manufacturing agreement.

The company is offering its rabbit clonal monospecific antibodies that can be used for the following applications: immunohistochemistry (IHC) on paraffin sections of the tissue biopsies, western blot, immunocytochemistry (ICC), immunoprecipitation (IP) and flow cytometry (FC) on blood and other body fluids samples. Its detection system is dual, mouse/rabbit, horseradish peroxidase (HRP) labelled micropolymer based secondary antibody conjugate, designed for applications in immunohistochemistry. It detects separately rabbit or mouse immunoglobulins, or both bound to an antigen presented in the tissue or cell samples.

Its proteomic services can be used for protein identification and characterisation studies very helpful in characterisation and diagnosis of immune system related, (neuro) degenerative disease, diabetes and cancer. Company is offering capacities of its fully equipped proteomic services laboratory or for development of the new antibodies, or for involvement in human diseases characterisation, diagnosis, potentially a treatment.

Based on distribution services agreement the antibodies and detection system could be distributed to potential new clients right away. Company has also capacities for design, development and production of new antibodies, based on specifications by a partner respectively based on services or manufacturing agreements.

Advantages and Innovations

All the products are produced locally, using unique technology, (propriety of the company) for design and production. This technology enables the design of antibodies even to complicated epitopes, eliminates some disadvantages of classical, hybridoma based technologies and produces highly specific, fully glycosylated antibodies. The company's products have usually higher avidity and affinity compared to others, enabling larger dilutions. The technology was proven to be effective in production of more than 140 antibodies already on the market. Company's products are currently distributed in the UK, France, the USA, Vietnam, Mexico, Turkey, Japan, just to mention a few, with overwhelmingly positive feedbacks.

The main advantages of its products are: instant availability (company is the manufacturer and is stocking all of them in place), short delivery terms and large price flexibility. Presence of the well-equipped proteomic laboratory on the premises is a big advantage, enabling combination of know-how and production capacities in the same unit.

Stage of Development

Already on the market

IPR Status

Secret Know-how

Comment Regarding IPR status

The technology and know-how was developed after more than 30 years of active experience in basic and applied research laboratories in Europe, USA and Canada, and is an exclusive property of the company.

Keywords

Market

05001001	Diagnostic services
05001002	In-vitro diagnostics
05001003	Differential diagnosis
05001005	Molecular diagnosis
05001007	Other diagnostic

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Client

Type and Size of Organisation Behind the Profile

Industry SME 11-49

Year Established

2007

Turnover

<1M

Already Engaged in Trans-National Cooperation

Yes

Client Country

Slovakia

Partner Sought

Type and Role of Partner Sought

Type of partners:

- Distributing partner
- Partner in developing new products
- Partner helping to finance R&D and production of a new product

Company has 140 ready to use antibodies already on the market, and these can be distributed to the clients right away. Also, there is a capacity for new partners available for the development of a new antibodies and for the use of company's proteomic services for human diseases characterisation, development of diagnostic tools and potentially for the treatment in the form of services or manufacturing agreement.

Type and Size of Partner Sought

SME 11-50,>500 MNE,SME 51-250,>500

Type of Partnership Considered

Services agreement
Manufacturing agreement
Distribution services agreement

Business Offer

UK sports nutrition company is seeking distributors for its range of premium sports nutritional supplements

Summary

Sports nutrition company based in the north east of England is offering to supply its range of premium sports nutritional supplements. The company is looking for European distributors who supply to health clubs, gyms and any other sports nutrition retailers. The company is offering a distribution agreement.

Creation Date 31 March 2016
Expiration Date 13 April 2017
Reference BOUK20160330001

Details

Description

This UK based sports nutrition company has over 10 years' experience in the pharmaceutical manufacturing and sports nutrition industries and has designed high quality and effective products using their experience and access to the latest research into sports nutrition.

Supplements are developed using the highest quality natural ingredients providing a premium blend of extracts and vitamins.

Product range includes supplements for;

Diet and weight control
Pre-workout
Protein
Nutrition
Recovery

Alongside their own range, the company also supplies an assortment of other branded nutritional supplements.

The company is looking to expand into the European market and is seeking distributors who can supply to health clubs, gyms and any other sports nutrition retailers.

The company is looking for new European partners who will act as a distributor for their products and is offering a distribution agreement.

Advantages and Innovations

- Developed by sports scientists with proven results
- Rapid worldwide despatch and shipping within 24 hours of order

- Every product 100% factory sealed
- Full quality guarantee on all orders

Stage of Development

Already on the market

Keywords

Market

05007007

Other medical/health related (not elsewhere classified)

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Client

Type and Size of Organisation Behind the Profile

Industry SME <= 10

Year Established

2015

Turnover

<1M

Already Engaged in Trans-National Cooperation

No.

Client Country

United Kingdom

Partner Sought

Type and Role of Partner Sought

Partner sought

Distributors who will supply the supplements to health clubs, gyms and any other sports nutrition retailers.

A distribution services agreement is offered to the distributor.

Type and Size of Partner Sought

SME 11-50, SME <10, >500 MNE, 251-500, SME 51-250, >500

Type of Partnership Considered

Distribution services agreement

Business Offer

Joint-venture partner sought for an innovative software supporting responsible self-medication

Summary

Portuguese start-up dedicated to the research, development and implementation of new pharmacy services and products is looking for partners abroad, interested in joint-venture agreements for internationalization. The company has developed a software to support both health professionals and patients in decision-making regarding responsible self-medication.

Creation Date 09 March 2016
Expiration Date 08 April 2017
Reference BOPT20160309002

Details

Description

Portuguese start-up that developed a specific disruptive software aimed to contribute to the decrease of drug related problems (DRP), which can be used by healthcare professionals and patients, is looking for similar companies abroad, interested in joint-venture agreements.

An aging population and the increasing prevalence of chronic diseases have led to the increased use of medicines. Although they are associated with enormous health benefits medicines can also cause illness and death. A drug related problem (DRP) is “an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes”.

Just in the United States of America, DRP is the 4th cause of death with an overall estimated cost of 130 billion dollars per year.

But DRP can be avoided and pharmacists play an important role since they are trained to know and understand medicines. The causes of DRP are related with the selection of the drug, its dosage, treatment's duration and other causes related to the logistics or the patient itself. The pharmaceutical interventions are targeted to prevent DRP and to contribute to the optimization of pharmacotherapy results.

The software developed by the Portuguese start-up is an online, interactive tool, can be used to support both health professionals and patients in decision-making regarding responsible self-medication.

Through the use of this software safe choices are made for each patient. The system also identifies potentially serious symptoms, where the patient should consult a doctor. The system has several functionalities like security alerts and patient information, among other features.

The company is also specialized in the provision of services and training to healthcare professionals associated with the safe use of medicines.

The start-up has now reached the commercial stage and is selling the software version for

healthcare professionals in Portugal.

As the software solves a global problem (and not just a Portuguese one) it is also the right moment to go international. As part of the international growth strategy, the company is looking for other companies abroad that could perform important tasks: to verify the national legislation, to verify and compile official information of every OTC medicines in that specific market and to translate the interface to other languages.

The software is prepared for the 55 different situations where self-medication is legally allowed in Portugal.

Advantages and Innovations

In developed countries, a large number of individuals use self-medication to treat minor ailments. Self-medication is a healthcare activity with considerable benefits for patients and healthcare systems, as long as appropriately supported by technical-scientific knowledge. The software the company developed intends to support both health professionals and patients in this healthcare activity. It is accessible online and its use is intuitive and simple.

The software works based on patient's clinical information and minor ailments presented, introduced in a simple and interactive way, in the main menu.

These options will determine if the patient presents any serious symptom and has to be referred to the doctor. Otherwise, the program suggests support measures and a list of over-the-counter (OTC) medications indicated to that specific symptom and adequate for the patient. It includes other functions that contribute to the correct use of OTC medications.

The software presents several advantages by helping daily decision making of healthcare professionals on the identification and selection of the more appropriate medicines, even in complex situations like polymedicated patients, patients with allergies/ intolerances, pregnant/breastfeeding women and children. In a similar but easier way, the software supports patients' decisions regarding self-medication.

The company has a high qualified staff comprising pharmacy and information technology (IT) specialists. The company is inserted in an innovation eco-system, being installed on a technology and science based incubator with access to the academia. This vibrant environment contributes to anticipate major developments in the sector and the company is continuously developing disruptive innovative services and products.

At international level, this year, the company participated in one of the main international IT Fair to showcase its solutions and to find relevant partners, in line with its growth strategy.

Stage of Development

Already on the market

IPR Status

Secret Know-how, Trade Marks

Keywords

Market

05001007	Other diagnostic
05003005	Drug delivery and other equipment
05007002	Pharmaceuticals/fine chemicals
05007006	Computer-aided diagnosis and therapy
05007007	Other medical/health related (not elsewhere classified)

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Client

Type and Size of Organisation Behind the Profile

Industry SME <= 10

Year Established

2014

Turnover

<1M

Already Engaged in Trans-National Cooperation

No.

Client Country

Portugal

Partner Sought

Type and Role of Partner Sought

The partners sought can be companies active in the sector related with pharmacy innovation, companies with a good network of pharmacies and parapharmacies and companies or organizations (for example cooperatives) dedicated to the distribution of medicines. Other potential partners are companies devoted to healthcare digital applications for patients.

The partner would be responsible for the verification and compliance with applicable national legislation, by the compilation and characterization of the national existent OTC medicines. The

partner is expected to translate the software to its own or other languages. Other possible task is to develop an app for patients using the logic structure already designed.

Type and Size of Partner Sought


SME 11-50, SME <10, >500 MNE, 251-500, SME 51-250, >500

Type of Partnership Considered


Joint venture agreement

Attachments

symptoms.png



ImagemPromo1.png



patiten.png

click to select system >

PATIENT

Blood

Cardiovascular system

Ear

Endocrine system

Eye

Gastrointestinal and metabolic system

General

Genitourinary system and sex hormones

Infections

Musculoskeletal system


Neoplasia and immune system

Nervous system

Parasites

Respiratory system

Skin



Technology Offer

Small electronic device for tracking Diabetes treatment

Summary

A Spanish SME has developed a small electronic device very easily plugged in any insulin injection pen, which helps patients automatically track critical information about their treatment, such as remembering the date, time and dosage of the last shot and the time of the next one. The SME is willing to sign a commercial agreement with technical assistance with companies from the pharmaceutical and health sector.

Creation Date	07 April 2016
Expiration Date	08 April 2017
Reference	TOES20160406001

Details

Description

A Spanish start-up company focused on e-health technologies provides an efficient solution for diabetic patients through a device that helps to manage the right administration of insulin in a controlled manner by an automatic tracking of critical information about the treatment, such as dates, times and dosages of the last shot. The technology consists in a small electronic device that is easily connected to any insulin injection pen and that sends, via Bluetooth, the information to a pre-installed app, keeping data in the Cloud for data warehouse and synchronization with multiple devices. The app helps diabetics and their doctors and caregivers to manage the disease along time.

Most relevant features:

- Mechanical resistance of the device.
- Redundancy-based reliability (data stored at both the device and the app).
- Usability of the app. iOS and Android devices being covered.
- Universality: it adjusts to any insulin pen.
- Small size, small weight.
- Long term duration of batteries (more than a year).
- Battery can be changed.

The SME would like to find companies from the pharmaceutical and health sector interested in signing a commercial agreement with technical assistance that would arrange the acquisition of the system paired with the provision of technical assistance in engineering and technical consultancy.

Advantages and Innovations

Main advantages for users:

- First wearable for the insulin pen. It allows an optimal follow up of the treatment and brings significant progress if compared to its competitors, since none of them connect the insulin pen with our mobile or send data to the Cloud to have a statistical control of medication
- Integrated in treatment routine. It has been designed to compile required data automatically, so

that patients do not really need to do anything else but carry on their treatment. Security does not longer depend on the scrupulosity of patients.

- Data requirements and alert systems have been adjusted to real and critical needs of diabetics (no more, no less), also considering the needs of their caregivers (for the first time).
- Temperature sensor included to assure the correct conservation of the insulin.

Main advantages for pharmaceutical, health insurer and healthcare provider companies:

- They can measure the adherence to treatment and this enables them to insure persons with diabetes, perform risk-shared agreements with pharmaceutical companies and give a better service to their clients.
- They are interested in the data generated by the device to know the habits of their consumers.
- It enables the possibility to implement a telemedicine system where physicians can monitor their patients more effectively: seeing in real time incidences and finding the ones with worse control to call and offer them support. The automatically generated data are more reliable, so the calculations performed by the physicians will be more useful.

Main benefits:

- Increased security and quality of life with no extra burden for patients.
- Self-control of the disease and empowerment.
- Support to caregivers for remotely monitoring and managing treatment.
- New business models for pharmaceutical and health insurance companies
- Better treatment of people with diabetes thanks to the telemedicine system
- Cost saving for healthcare providers

Stage of Development

Available for demonstration

Comments Regarding Stage of Development

In October 2016 the commercial version will be ready and will start production. Pilot trials have been carried out in Spain and American Hospitals.

IPR Status

Secret Know-how, Design Rights, Patent(s) applied for but not yet granted, Trade Marks, Exclusive Rights, Copyright, Other

Comment Regarding IPR status

Spanish patent and European Industrial design granted. European patent pending.

Profile Origin

Private (in-house) research

Keywords

Market

05003005

Drug delivery and other equipment

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Client**Type and Size of Organisation Behind the Profile**

Industry SME <= 10

Year Established

0

Already Engaged in Trans-National Cooperation

No.

Client Country

Spain

Partner Sought**Type and Role of Partner Sought**

The SME would like to find companies from the pharmaceutical and health sector interested in signing a commercial agreement with technical assistance that would arrange the acquisition of the system paired with the provision of technical assistance in engineering and technical consultancy.

Type and Size of Partner Sought

SME 11-50,>500 MNE,251-500,SME 51-250,>500

Type of Partnership Considered

Commercial agreement with technical assistance

Technology Offer

Differential diagnosis of dementia with Lewy bodies and Parkinson's disease

Summary

German scientists developed a new diagnostic approach to differentiate between Dementia with Lewy bodies (DLB), Parkinson's disease (PD) and other neuropathies. They are looking for commercializing and licensing partners in the diagnostic field.

Creation Date 21 April 2016
Expiration Date 28 April 2017
Reference TODE20160421001

Details

Description

Parkinson's disease (PD) is a neurodegenerative disorder affecting about 1% of the population over 65 years. Atypical Parkinson syndrome arise generally from other neurodegenerative diseases like Dementia with Lewy bodies (DLB). The accurate distinction between Parkinson's disease, dementia with Lewy bodies and other non-alpha-synuclein variants with Parkinson syndrome is challenging due to an overlap of clinical symptoms and neuropathological changes. University scientists developed a new diagnostic approach to differentiate between DLB, PD and other neuropathies.

There is currently no assay or imaging method available that provides security for clinical diagnosis of Parkinson's disease and atypic Parkinson syndromes. As a consequence, atypic Parkinson syndromes are often misdiagnosed as idiopathic Parkinson disease, which may lead to long-lasting mistherapy. Accordingly, there is an unmet need for methods of differential diagnosis of dementia with Lewy bodies, Parkinson's disease and other non-alpha-synuclein variants with Parkinson-like syndromes.

The provided solution is a new developed diagnostic approach to differentiate between DLB, PD and other neuropathies by:

- extracting exosomes from cerebrospinal fluid (CSF patient samples)
- counting number of exosomes
- measuring the amount of exosomal alpha-synuclein.

Potential applications are:

- Diagnosis of PD using CSF patient samples
- Diagnosis of DLB using CSF patient samples
- Differential diagnosis DLB vs PD and/or vs other non-PD, non-dementia neurological disorders (e.g. PNP, PSP)

The scientists interested in commercialization and are looking for licensing partners in the diagnostic field (in-house diagnostics or diagnostic test kit provider).

Advantages and Innovations

- Differential diagnosis based on sub-population of widely accepted biomarker alpha-synuclein
- Robust diagnosis due to evaluation of “shielded” alpha-synuclein in exosomes
- Use of an internal control parameter in patient's samples (number of exosomes)
- Differential diagnosis of DLB vs PD with a high sensitivity (>0.85) and...
- ...High specificity (>0.80) – more than twice compared to CSF alpha-synuclein (total amount)
- Validated on patient's CSF sample in a clinical cohort of >100

Stage of Development

Under development/lab tested

Comments Regarding Stage of Development

The diagnostic test has been validated on patient's CSF sample in a clinical cohort of >100.

IPR Status

Patent(s) applied for but not yet granted

Comment Regarding IPR status

A priority patent application has been filed.

Profile Origin

National or Regional R&D programme

Keywords

Market

05001001	Diagnostic services
05001003	Differential diagnosis

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Client

Type and Size of Organisation Behind the Profile

University

Year Established

0

Already Engaged in Trans-National Cooperation

Yes

Client Country

Germany

Partner Sought

Type and Role of Partner Sought

We are looking for partners active in the development and market activities in the diagnostic test market, ideally with a focus on differential diagnosis of neurodegenerative illnesses, like dementia or Parkinson's disease.

Type of Partnership Considered

License agreement

Technology Offer

Lithuanian company offers blood modeling and simulation services in capillaries and biologically active materials as well as transport across cells' membranes

Summary

Lithuanian SME offers services for computer modeling (creation of models) and simulation (using Monte Carlo methods) of biologically active materials transport processes in capillaries and across cells' membranes. The models can be also applied to transportation of molecules of drugs and radioactive nuclides being injected to the human body. Company is seeking for industrial partners, R&D institutions for commercial, financial or research cooperation agreements.

Creation Date	01 April 2016
Expiration Date	04 April 2017
Reference	TOLT20160401001

Details

Description

Lithuanian small scientific research company is working in the following fields:

- 1) mathematical and computer modeling and simulation of physical and technological processes;
- 2) creation of mathematical and computer business (industry, construction, services, social) models, simulation of various scenarios, and preparation of detailed business plans based on modeling & simulation results.

Project is devoted for the modeling and simulation of the following:

- 1) transport of the active biological materials (including carriers of radioactive nuclides) in blood media via capillaries;
- 2) transport across the cells' membranes via different membrane transport channels;
- 3) further biochemical reactions' kinetics in the cells (in the case of further project's development).

The main idea is to switch from phenomenological kinetics to statistics of direct molecule-molecule, molecule-(cell membrane channel) processes. There have to be the dynamic picture of evolution of various molecules in time, space and their (molecules) internal structure change. For the achievement of those purposes there have to be constructed the models of atom/ion (radioactive nuclide)-molecule, molecule-molecule, and molecule-(various cell membrane channels) interactions.

The ensembles of large amount of test molecules have to be taken for the simulations of their dynamical evolution.

The Monte Carlo methods (methods of stochastic simulation) will be used for the numerical simulations of all those processes.

Each process and object will be modeled by use of different approaches as follows:

- 1) original phenomenological models;
- 2) models based on interpolation and approximation of experimental data;

- 3) models based on different theoretical approaches;
- 4) numerical models;
- 5) hybrid models.

For the further simulations of evolution of molecules' ensembles, those mathematical models have to have the simple mathematical forms, or in other cases they have to be interpolated via simple numerical expressions (for example - Pade approximation, etc.).

There will be created the sets of working models with different complexity and accuracy for each physical and biochemical process and object.

The "Final model" (an integrated model involving all processes and evolution of molecules' ensembles) is dynamic, i.e. there is the permanent development phase (of project) giving the pictures of processes with different accuracy, but giving intermediate results in early phases of researches.

During the TO realization time there will be created a set of "Final models" with different levels of complexity. That R&D strategy enables to shorten the products' creation time.

There will be used high-level powerful programming language C++.

During this work the fully original special computer software (the features of transport of blood and injected biological/chemical/ionic materials in capillaries; complex transport across cell membranes; possible generation of new transport channels (or modification of existing) in cells' membranes) will be created.

Using results of various scenarios of simulations the phenomenological kinetic coefficients of various kinetic processes will be calculated.

The simulation results (including all intermediate results for each process) will be compared with experimental and theoretical data being published in various journals, monographs and gotten via private communications.

Company is looking for partners being interested in above mentioned results/products.

The sought partners would be active in engineering, industry, business or researches.

Advantages and Innovations

Current technological offer (TO) is oriented to the following:

1. Scientific knowledge:

- 1) creation of new original models of physical-chemical-biological processes taken place in transport of biological materials and radioactive nuclides in capillaries and across cells' membranes;
- 2) test of existing models;
- 3) more deep understanding of processes via use of various theoretical approaches in modeling and simulation;
- 4) calculation of kinetic coefficients of traditional kinetic equations via use of results of numerical modeling and simulations.

2. Practical applications:

- 1) simulation of real drug transport in human body including further biochemical reactions in the cells;
- 2) creation of empirical numerical models (based on project's simulations) for the fast estimation of various physiological situations in practice.
- 3) calculate the space and time distribution of injected radioactive nuclides and special active biological structures (for example drugs) in human body;
- 4) help in diagnostics and pharmacological treatment.

Cooperation/collaboration with pharmacological and medical engineering companies has to form the problems being top for them and having to be solved in the frame of current project (via direct modeling and simulation of problematic situations taken place in above mentioned fields).

Stage of Development

Proposal under development

Comments Regarding Stage of Development

The company has a large experience in mathematical modelling and computer simulation (especially in use of Monte Carlo methods) of physical processes (transport in semiconductors, microelectronics, high energy laser technologies, low-temperature plasma, directed energy technologies (including military), ecological environment, etc.).

IPR Status

Secret Know-how

Profile Origin

Other

Keywords

Market

05002005	Other medical imaging
05005014	Oncology
05005018	Medical Physics, Physiology
05005020	Forensic Medicine
05005021	Medical computer sciences

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Client

Type and Size of Organisation Behind the Profile

Industry SME <= 10

Year Established

1995

Turnover

<1M

Already Engaged in Trans-National Cooperation

No.

Client Country

Lithuania

Partner Sought

Type and Role of Partner Sought

Type of partner sought:

- industrial partners (large companies or SME), R&D institutions from the fields of medical & pharmacy, medical equipment manufactures to cooperate in developing specific software, to test and evaluate it.

Task to be performed by the partner sought:

- to test and evaluate software with a view to considering commercial, financial or research cooperation agreements.

Type and Size of Partner Sought

R&D Institution,251-500,SME 51-250,>500

Type of Partnership Considered

Financial agreement

Commercial agreement with technical assistance

Research cooperation agreement

Technology Offer

UK university developing a novel device for assessing macular pigment optical density seeks pharmaceutical producers, lens/medical device manufacturers

Summary

A vision scientist and neuroethologist at the school of biological sciences of a UK university seeks pharmaceutical producers, lens/medical device manufacturers to help take the technology from research level prototype to commercial product. The technology is a non-invasive novel device for assessing macular pigment optical density. Partners are sought on a commercial agreement with technical assistance or technical cooperation agreement basis.

Creation Date 24 March 2016
Expiration Date 01 April 2017
Reference TOUK20160324001

Details

Description

A vision scientist and neuroethologist at the school of biological sciences of a leading UK university has developed a novel approach/technology to diagnose important aspects of human eye health. The device can give an estimate of someone's macular pigment density linked with the patient's chances of going blind later in life from age related macular degenerations (AMD).

AMD is the leading cause of incurable blindness in the western world. Research indicates that AMD currently affects more than 600,000 people in the UK and is the leading cause of vision loss, by 2020 it's predicted almost 700,000 people will have late-stage AMD in the UK. The condition is most common in people over the age of 50. It's estimated 1 in every 10 people over 65 have some degree of AMD and with no cure for either type of AMD early diagnosis is essential for reducing the risk of severe vision loss. Macular pigments can only be acquired through your diet and so it is important to assess your macular pigment density as an indicator for eye health.

Complex equipment is available to detect/diagnose AMD however market research demonstrates that there is a potential market opportunity for niche technologies. The technology developed is a non-invasive, rapid and affordable device that measures an aspect of the health of the human eye (macular pigment concentration). In under two minutes this simple non-invasive visual test can tell someone if their macular pigment concentration is low, in which case they are already suffering low contrast sensitivity and poor vision due to glare, but may also be at risk for later developing age-related macular degeneration, the leading cause of incurable blindness in the UK. The test could be used as part of regular optometry or GP health checks as a tool for measuring eye health, potentially preventing AMD. It could also be used to inform people if they should consider purchasing eye vitamins/supplements or get UV-blue blocking coatings put on the lenses of their prescription glasses.

Preliminary clinical trials demonstrate that this technology is at least as accurate in assessing macular pigment optical density as the best available technology presently available. Market research is in progress to understand how this new technology could find a place in modern medical practice and specifically eye health exams performed by optometrists.

Collaborations on a commercial agreement with technical assistance or technical cooperation agreement basis are sought to inform market assessment, further product development and commercialisation strategy.

Advantages and Innovations

Whilst complex equipment is available to detect/diagnose AMD there is a demonstrated market opportunity for niche technologies that would allow:

- rapid (less than 2 minutes) non invasive threshold test for AMD that can potentially also be used as a prevention tool
- significantly reduced cost and much easier to use compared to existing technologies currently on the market
- not limited to use by optometrists but potential uses in food supplement manufactures and dietitians, also potential for global appeal if considering the wider impacts of AMD and correlation to diet in under developed countries.

The technology developed provides:

- a non invasive threshold test that rapidly assesses macular pigment density that can potentially also be used as a prevention tool for AMD
- novel approach enables significantly reduced cost compared to existing technologies currently on the market
- unlike all previous technologies for measuring macular pigments, this new approach is exceptionally easy to use for both clinician and subject, and has an extremely small footprint (hand held device)
- not limited to use by optometrists but potential uses in food supplement manufactures and dietitians, also potential for global appeal if considering the wider impacts of AMD and correlation to diet in under developed countries.

Stage of Development

Prototype available for demonstration

IPR Status

Patent(s) applied for but not yet granted

Profile Origin

Other

Keywords

Market

05001007	Other diagnostic
05004004	Medical instruments
05004005	Diagnostic equipment

05007004

Monitoring equipment

05007007

Other medical/health related (not elsewhere classified)

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : **Yes**

Client

Type and Size of Organisation Behind the Profile

University

Year Established

0

Already Engaged in Trans-National Cooperation

Yes

Client Country

United Kingdom

Partner Sought

Type and Role of Partner Sought

Partners are sought to help take the technology from research level prototype to commercial product. Of specific of interest are industrial partners including pharmaceutical producers, lens manufacturers and medical device manufacturers who can inform/support the development, practical application and role out of the new technology. For example as follows:

- pharmaceutical companies that produce eye supplements that contain macular carotenoids to

Partnering Opportunity

help assess market size/opportunity and future resale opportunities

- optometry/ophthalmology device and lens manufacturers to discuss the product development pathway, costs associated with development/certification and future resale opportunities.

Collaborations on a commercial agreement with technical assistance or technical cooperation agreement basis are sought to explore the commercial viability of taking the new technology to market.

Type and Size of Partner Sought

SME 11-50, Inventor, R&D Institution, SME <10, >500 MNE, 251-500, SME 51-250, >500

Type of Partnership Considered

Commercial agreement with technical assistance
Technical cooperation agreement